Study to Evaluate the Efficacy and Safety of Reslizumab Treatment in Patients With Moderate to Severe Asthma
Status:
Completed
Trial end date:
2013-08-01
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to characterize the efficacy of reslizumab treatment,
at a dosage of 3.0 milligrams per kilogram (mg/kg) every 4 weeks for a total of 4 doses, in
improving pulmonary function in relation to baseline blood eosinophil levels in patients with
moderate to severe asthma, as assessed by the change from baseline to week 16 in forced
expiratory volume in 1 second (FEV1).
Phase:
Phase 3
Details
Lead Sponsor:
Teva Branded Pharmaceutical Products R&D, Inc. Teva Branded Pharmaceutical Products, R&D Inc.